We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

CombiGene and Cobra Biologics Sign Gene Therapy Production Agreement

News   Sep 10, 2020

 
CombiGene and Cobra Biologics Sign Gene Therapy Production Agreement

Credit: geralt/Pixabay

 
 
Advertisement
 

RELATED ARTICLES

Major Step Toward Angelman Syndrome Gene Therapy

News

Babies born with a faulty maternal copy of the UBE3A gene will develop Angelman syndrome, a severe neurodevelopmental disorder with no cure and limited treatments. Now, for the first time, scientists at the UNC School of Medicine show that gene editing and gene therapy techniques can be used to restore UBE3A in human neuron cultures and treat deficits in an animal model of Angelman syndrome.

READ MORE

A Potential Diagnostic Test and Molecular Target for Machado-Joseph Disease

News

Researchers have developed a potential test for Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3), a disease that currently has no cure. The team has also have uncovered the role of a gene target linked to the disease.

READ MORE

Anti-Inflammatory Drug Reduces Disease Progression in Preclinical Model of MS

News

Intranasal administration of an anti-inflammatory drug helped reduce disease progression in a preclinical model of multiple sclerosis, according to recent research out of the University of Alberta.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE